Comparison · NCT01120028-da2abe3b
Period 2: Sirolimus vs Period 2: Tacrolimus: Number of Participants With Cancer (at 18-months After Randomization to Maintenance Therapy)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Period 2: Sirolimus vs Period 2: Tacrolimus: Number of Participants With Cancer (at 18-months After Randomization to Maintenance Therapy). Trial comparisons, record NCT01120028-da2abe3b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01120028-da2abe3b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0863 | 0.0546 | 0.134 | wilson | |
| Risk in group 2 | 0.0863 | 0.0546 | 0.134 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.0572 | 0.0572 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.526 | 1.9 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.495 | 2.02 | log | |
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Period 2: Sirolimus | Sirolimus maintenance therapy: target trough level of 6-12 ng/mL for the first 6-months, then reducing to 5-10 ng/mL. | 17 | 197 | OG000 |
| Group 2 | Period 2: Tacrolimus | Tacrolimus maintenance therapy: target trough level of 5-7 ng/mL | 17 | 197 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Cancer (at 18-months After Randomization to Maintenance Therapy)
- Description
- Occurrence of any cancer reported during Period 2 (maintenance therapy randomization to either Sirolimus or Tacrolimus).
- Time frame
- 2 years post-transplantation
- Population
Source ClinicalTrials.gov
Trial
- Title
- Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
- NCT number
- NCT01120028
- Phases
- PHASE2, PHASE3
- Conditions
- Kidney Transplantation
- Interventions
- Alemtuzumab, Basiliximab, Sirolimus, Tacrolimus
- Lead sponsor
- University of Oxford
- Results first posted
- 2019-10-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01120028?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01120028-da2abe3b